Comparative Pharmacology

Head-to-head clinical analysis: LIDOCAINE VISCOUS versus PARACAINE.

Peer-Reviewed Evidence

Differential Analysis

LIDOCAINE VISCOUS vs PARACAINE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

LIDOCAINE VISCOUS

Local Anesthetic / Antiarrhythmic (Class Ib)

Category A/B

PARACAINE

Local Anesthetic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels (Nav1.7, Nav1.8) in neuronal membranes, inhibiting depolarization and propagation of action potentials, thereby producing local anesthesia. It also has antiarrhythmic properties (class IB) by blocking sodium channels in cardiac myocytes.

Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.

Clinical Dosing

15 mL (300 mg) orally every 3 hours as needed for pain; maximum 8 doses per 24 hours.

10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.

Direct Interaction

None Documented

Half-Life

Terminal elimination half-life is 1.5–2 hours (up to 3 hours in hepatic impairment). Clinically, redistribution half-life (~6 min) determines duration of action after short infusions.

Other Significant Interactions

Clinical Note

moderate

Proparacaine + Fluticasone propionate

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."

Clinical Note

moderate

Proparacaine + Clemastine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."

Clinical Note

moderate

Proparacaine + Venlafaxine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."

Clinical Note

moderate